Logo image of PTPI

PETROS PHARMACEUTICALS INC (PTPI) Stock Fundamental Analysis

NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD

0.0664  -0.06 (-46.45%)

After market: 0.0356 -0.03 (-46.39%)

Fundamental Rating

1

PTPI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. PTPI has a bad profitability rating. Also its financial health evaluation is rather negative. PTPI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PTPI has reported negative net income.
PTPI had a negative operating cash flow in the past year.
In the past 5 years PTPI always reported negative net income.
In the past 5 years PTPI always reported negative operating cash flow.
PTPI Yearly Net Income VS EBIT VS OCF VS FCFPTPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

PTPI has a worse Return On Assets (-251.96%) than 92.39% of its industry peers.
Industry RankSector Rank
ROA -251.96%
ROE N/A
ROIC N/A
ROA(3y)-118.22%
ROA(5y)-79.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTPI Yearly ROA, ROE, ROICPTPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

PTPI's Gross Margin of 76.28% is amongst the best of the industry. PTPI outperforms 84.26% of its industry peers.
PTPI's Gross Margin has improved in the last couple of years.
PTPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.38%
GM growth 5Y7.84%
PTPI Yearly Profit, Operating, Gross MarginsPTPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTPI has been increased compared to 1 year ago.
Compared to 5 years ago, PTPI has more shares outstanding
Compared to 1 year ago, PTPI has a worse debt to assets ratio.
PTPI Yearly Shares OutstandingPTPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
PTPI Yearly Total Debt VS Total AssetsPTPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -18.76, we must say that PTPI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -18.76, PTPI is not doing good in the industry: 80.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.76
ROIC/WACCN/A
WACC6.75%
PTPI Yearly LT Debt VS Equity VS FCFPTPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.40 indicates that PTPI may have some problems paying its short term obligations.
With a Current ratio value of 0.40, PTPI is not doing good in the industry: 93.91% of the companies in the same industry are doing better.
A Quick Ratio of 0.33 indicates that PTPI may have some problems paying its short term obligations.
PTPI's Quick ratio of 0.33 is on the low side compared to the rest of the industry. PTPI is outperformed by 93.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.33
PTPI Yearly Current Assets VS Current LiabilitesPTPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.32% over the past year.
PTPI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -57.42%.
Measured over the past years, PTPI shows a very negative growth in Revenue. The Revenue has been decreasing by -19.98% on average per year.
EPS 1Y (TTM)14.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320.26%
Revenue 1Y (TTM)-57.42%
Revenue growth 3Y-13.17%
Revenue growth 5Y-19.98%
Sales Q2Q%-87.54%

3.2 Future

The Earnings Per Share is expected to grow by 18.51% on average over the next years. This is quite good.
Based on estimates for the next years, PTPI will show a very strong growth in Revenue. The Revenue will grow by 43.00% on average per year.
EPS Next Y48.83%
EPS Next 2Y21.8%
EPS Next 3Y18.67%
EPS Next 5Y18.51%
Revenue Next Year0.76%
Revenue Next 2Y0.17%
Revenue Next 3Y26.71%
Revenue Next 5Y43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PTPI Yearly Revenue VS EstimatesPTPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PTPI Yearly EPS VS EstimatesPTPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTPI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTPI Price Earnings VS Forward Price EarningsPTPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTPI Per share dataPTPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

PTPI's earnings are expected to grow with 18.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.8%
EPS Next 3Y18.67%

More info and screens

0

5. Dividend

5.1 Amount

PTPI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (5/21/2025, 8:00:01 PM)

After market: 0.0356 -0.03 (-46.39%)

0.0664

-0.06 (-46.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners1.13%
Inst Owner Change0%
Ins Owners1.01%
Ins Owner Change95.98%
Market Cap2.07M
Analysts82.86
Price TargetN/A
Short Float %1.2%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.63%
Min Revenue beat(2)-44.58%
Max Revenue beat(2)15.32%
Revenue beat(4)1
Avg Revenue beat(4)-8.97%
Min Revenue beat(4)-44.58%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-91.45
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.16
BVpS-0.24
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -251.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.28%
FCFM N/A
ROA(3y)-118.22%
ROA(5y)-79.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.38%
GM growth 5Y7.84%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.87%
Cap/Sales 0.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.33
Altman-Z -18.76
F-Score5
WACC6.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320.26%
EPS Next Y48.83%
EPS Next 2Y21.8%
EPS Next 3Y18.67%
EPS Next 5Y18.51%
Revenue 1Y (TTM)-57.42%
Revenue growth 3Y-13.17%
Revenue growth 5Y-19.98%
Sales Q2Q%-87.54%
Revenue Next Year0.76%
Revenue Next 2Y0.17%
Revenue Next 3Y26.71%
Revenue Next 5Y43%
EBIT growth 1Y53.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.87%
OCF growth 3YN/A
OCF growth 5YN/A